ReviewCancers2022
Inflammatory Myofibroblastic Tumour: State of the Art.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Inflammatory myofibroblastic tumor of the psoas muscle presenting as a retroperitoneal mass: a case report.International journal of surgery case reports · 2026Article
- Gene Expression Profiling ofJournal of clinical practice and research · 2026Article
- Molecularly guided management of pediatric endobronchial inflammatory myofibroblastic tumor: a report of two cases on surgical and targeted intervention.Translational pediatrics · 2026Article
- Thoracic inflammatory myofibroblastic tumors: A decade-long retrospective study integrating clinicopathological and molecular features from a tertiary care centre.Virchows Archiv : an international journal of pathology · 2026Article
- Inflammatory-myofibroblastic tumour with acute calculous cholecystitis in a sessile gall bladder in a young woman.Journal of surgical case reports · 2026Article
- Un uncommon diagnosis of liver masses.Internal and emergency medicine · 2026Article
- Rare Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Case Report and Review of the Literature.Journal of clinical medicine · 2026Article
- Article
- Case Report:Frontiers in oncology · 2026Article
- Inflammatory myofibroblastic tumour: unravelling the interplay of inflammation, kinase signalling, and therapeutic resistance.Frontiers in oncology · 2026Review
- Unexpected complete resolution of intravesical inflammatory myofibroblastic tumor after immunotherapy for melanoma: A case report.Urology case reports · 2026Article
- Case Report: Single-cell transcriptomic profiling of a pediatric ALK-negative gastric inflammatory myofibroblastic tumor.Frontiers in immunology · 2026Article
- Article
- Clinical features analysis of inflammatory myofibroblastic tumors of the retroperitoneal and genitourinary system.BMC urology · 2025Article
- Anlotinib for the treatment of pulmonary epithelioid inflammatory myofibroblastic sarcoma: a case report.Anti-cancer drugs · 2025Article
- Article
- Clinical Characteristics, Diagnosis, and Management of Primary Malignant Lung Tumors in Children: A Single-Center Analysis.Biomedicines · 2025Article
- Clinical diagnosis and treatment of abdominal inflammatory myofibroblastic tumors.Discover oncology · 2025Article
- Inflammatory Myofibroblastic Tumor: An Updated Review.Cancers · 2025Review
- Inflammatory myofibroblastic tumor of the adrenal gland: A case report.International journal of surgery case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An inflammatory myofibroblastic tumor (IMT) is a neoplasm composed of myofibroblastic and fibroblastic spindle cells accompanied by inflammatory cells, including lymphocytes and eosinophils. It is an ultra-rare tumor, the optimal management of which remains to be defined. Surgery is the treatment of choice for localized tumors. The treatment of advanced disease is not precisely defined. Chemotherapy regimens result in an overall response rate of approximately 50% based on retrospective data. The latest pathophysiological data highlight the role played by tyrosine kinase fusion genes in IMT proliferation. Anaplast lymphoma kinase (ALK) oncogenic activation mechanisms have been characterized in approximately 80% of IMTs. In this context, data regarding targeted therapies are most important. The aims of this article are to review the latest published data on the use of systematic therapy, particularly the use of molecular targeted therapy, and to publish an additional case of an IMT with Ran-binding protein 2 (RANPB2)-ALK fusion showing a long response to a tyrosine kinase inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.